Skip to main content

Crohn's & Colitis
blogs, news & research


Cross-immunogenicity: antibodies to infliximab in Remicade-treated patients with IBD similarly recognise the biosimilar Remsima

By Shomron Ben-Horin, Miri Yavzori, Itai Benhar, Ella Fudim, Orit Picard, Bella Ungar, SooYoung Lee, SungHwan Kim, Rami Eliakim, Yehuda Chowers

Scientists conducted a study on 125 patients to test the cross-immunogenicity of the approved infliximab-biosimilar Remsima (CT-P13) with the originator drug Remicade. They found that Anti-Remicade antibodies within patients with IBD had the effect of functionally inhabiting Remsima to a similar degree. This is suggestive of common immunogenicity and shared immunodominant epitopes on these two infliximab agents. When compared with anti-adalimumab antibodies scientists noted no cross-reaction with Remsima or Remicade.

Crohn’s and Colitis Australia would like to thank BMJ Journals for permission to use this article.



Posted on: February 23 2018

Leave a comment

Your email address will not be published. Required fields are marked *

No comments found.

About the author

Crohns & Colitis